Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KEM2104
- Development stage
- Phase 2
- Lead developer
- 长沙晶易医药
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
KEM2104 is a small molecule drug candidate developed for transdermal administration, currently under investigation for the treatment of osteoarthritis. Its precise mechanism of action has not been disclosed or remains unknown. The product is being developed by Changsha Jingyi Pharmaceutical Technology Co., Ltd. There are no approved indications or known adverse events reported to date. Clinical development includes a Phase 1 trial in osteoarthritis and an additional study in healthy volunteers evaluating single and multiple dosing as well as bioavailability[1][3].
Beyond the preview
Go deeper on KEM2104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KEM2104.